today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate the Company’s Cell Pouch auto-transplanted with ...

COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed ...

“FDA clearance of our IND application, combined with the encouraging data from our phase 1 healthy volunteer trial, provide tremendous momentum for the ABX1100 clinical development program ...

Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD) Announcement coincides with WORLDSymposium ...

“Clearance of the IND application for CNP-103 is a notable moment for COUR, as CNP-103 will be our third proprietary autoimmune disease program developed using our nanoparticle platform for ...

IND, application for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR T product. The Phase 1 RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ...